Novel perspectives on the hepatitis B virus vaccine in the chronic kidney disease population

International Journal of Artificial Organs

Volumn 38, Issue 12, 2015, Pages 625-631

  Fabrizi, Fabrizio ^a   Martin, Paul ^b   Messa, Piergiorgio ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvants; Chronic kidney disease; Hepatitis B virus; Third generation vaccine; Vaccine

Indexed keywords

ALUMINUM COMPOUNDS; DIALYSIS; DISEASES; IMMUNE SYSTEM; MAMMALS; RECOMBINANT PROTEINS; VIRUSES;

ADJUVANT; CHRONIC KIDNEY DISEASE; HEPATITIS B VIRUS; IMMUNE RESPONSE; IMMUNOGENICITY; LIPID A; PREVALENCE RATES; SECOND GENERATION; THIRD GENERATION; THIRD-GENERATION VACCINE;

VACCINES;

3 O 4 DESACYL MONOPHOSPHORYL LIPID A; 3 O DESACYL 4 MONOPHOSHORYL LIPID A; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LEVAMISOLE; PHOSPHORYL LIPID A; POLY(METHYL METHACRYLATE); QS 21; QUILLAJA SAPONIN; RECOMBINANT HEPATITIS B VACCINE; THYMOPENTIN; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; HEPATITIS B ANTIBODY; IMMUNOLOGICAL ADJUVANT; RECOMBINANT VACCINE;

CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; GENE INSERTION; HUMAN; IMMUNOGENICITY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMBINANT DNA TECHNOLOGY; REVIEW; SACCHAROMYCES CEREVISIAE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VACCINE FAILURE; ADVERSE EFFECTS; BLOOD; DRUG DESIGN; HEMODIALYSIS; HEPATITIS B, CHRONIC; IMMUNOLOGY; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; BIOMARKERS; DRUG DESIGN; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

EID: 84957885133     PISSN: 03913988     EISSN: 17246040     Source Type: Journal    
DOI: 10.5301/ijao.5000458     Document Type: Review

References (47)

1. Fabrizi F, Martin P. Hepatitis B virus infection in dialysis patients. Am J Nephrol. 2000;20(1):1-11.
2. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18(1):52-61.
3. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50:1-43. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5005a1.htm. Accessed January 3, 2015.
4. Girndt M, Köhler H. Hepatitis B virus infection in hemodialysis patients. Semin Nephrol. 2002;22(4):340-350.
5. Crosnier J, Jungers P, Couroucé AM, et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients. Lancet. 1981;1(8224):797-800.
6. Desmyter J, Colaert J, De Groote G, et al. Leuven Renal Transplantation Collaborative Group. Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Doubleblind placebo-controlled trial. Lancet. 1983;2(8363):1323-1328.
7. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W; Dialysis Vaccine Trial Study Group. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med. 1984;311(8):496-501.
8. Grzegorzewska AE. Hepatitis B vaccination in chronic kidney disease patients: a call for novel vaccines. Expert Rev Vaccines. 2014;13(11):1317-1326.
9. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta- analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. Aliment Pharmacol Ther. 2004;20(10):1053-1062.
10. Alavian SM, Tabatabaei SV. The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: A meta-analysis of current literature. Vaccine. 2010;28(22):3773-3777.
11. Fabrizi F, Dixit V, Martin P, Messa P. Erythropoietin use and immunogenicity of hepatitis B virus vaccine in chronic kidney disease patients: a meta-analysis. Kidney Blood Press Res. 2012;35(6):504-510.
12. Lombardi M, Pizzarelli F, Righi M, et al. Hepatitis B vaccination in dialysis patients and nutritional status. Nephron. 1992;61(3):266-268.
13. Fabrizi F, Dixit V, Martin P, Jadoul M, Messa P. Meta-analysis: the impact of nutritional status on the immune response to hepatitis B virus vaccine in chronic kidney disease. Dig Dis Sci. 2012;57(5):1366-1372.
14. Navarro JF, Teruel JL, Mateos ML, Marcen R, Ortuno J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol. 1996;16(2):95-97.
15. Fabrizi F, Dixit V, Martin P, Messa P. Hepatitis C virus and the immunological response to hepatitis B virus vaccine in dialysis patients: meta-analysis of clinical studies. J Viral Hepat. 2011;18(12):871-876.
16. Jibani MM, Heptonstall J, Walker AM, Bloodworth LO, Howard AJ. Hepatitis B immunization in UK renal units: failure to put policy into practice. Nephrol Dial Transplant. 1994;9(12):1765-1768.
17. Pol S, Legendre C, Mattlinger B, Berthelot P, Kreis H. Genetic basis of nonresponse to hepatitis B vaccine in hemodialyzed patients. J Hepatol. 1990;11(3):385-387.
18. Ahuja TS, Kumar S, Mansoury H, Rodriguez H, Kuo YF. Hepatitis B vaccination in human immunodeficiency virus-infected adults receiving hemodialysis. Kidney Int. 2005;67(3):1136-1141.
19. Fabrizi F, Dixit V, Bunnapradist S, Martin P. Meta-analysis: the dialysis mode and immunological response to hepatitis B virus vaccine in dialysis population. Aliment Pharmacol Ther. 2006;23(8):1105-1112.
20. Afsar B, Elsurer R, Eyileten T, Yilmaz MI, Caglar K. Antibody response following hepatitis B vaccination in dialysis patients: does depression and life quality matter? Vaccine. 2009;27(42):5865-5869.
21. Zitt E, Sprenger-Mähr H, Knoll F, Neyer U, Lhotta K. Vitamin D deficiency is associated with poor response to active hepatitis B immunisation in patients with chronic kidney disease. Vaccine. 2012;30(5):931-935.
22. Hashemi B, Mahdavi-Mazdeh M, Abbasi M, Hosseini- Moghaddam SM, Zinat NH, Ahmadi F. Efficacy of HBV vaccination in various stages of chronic kidney disease: is earlier better? Hepat Mon. 2011;11(10):816-820.
23. DaRoza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis. 2003;42(6):1184-1192.
24. Ghadiani MH, Besharati S, Mousavinasab N, Jalalzadeh M. Response rates to HB vaccine in CKD stages 3-4 and hemodialysis patients. J Res Med Sci. 2012;17(6):527-533.
25. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. Section VI. Haemodialysisassociated infection. Nephrol Dial Transplant. 2002;17(Suppl 7):72-87.
26. Shouval D, Roggendorf H, Roggendorf M. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine. Med Microbiol Immunol. 2015; 204(1):57-68.
27. Shouval D, Ilan Y, Adler R, et al. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine. 1994;12(15):1453-1459.
28. Leroux-Roels G, Desombere I, De Tollenaere G, et al. Hepatitis B vaccine containing surface antigen and selected pre-S1 and pre-S2 sequences Safety and immunogenicity in young, healthy adults. Vaccine. 1997;15(16):1724-1731.
29. Jungers P, Chauveau P, Couroucé AM, et al. Immunogenicity of the recombinant GenHevac B Pasteur vaccine against hepatitis B in chronic uremic patients. J Infect Dis. 1994;169(2):399-402.
30. Weinstein T, Chagnac A, Boaz M, et al. Improved immunogenicity of a novel third-generation recombinant hepatitis B vaccine in patients with end-stage renal disease. Nephron Clin Pract. 2004;97(2):c67-c72.
31. Waite NM, Thomson LG, Goldstein MB. Successful vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine. J Am Soc Nephrol. 1995;5(11):1930-1934.
32. Marangi AL, Giordano R, Montanaro A, et al. Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination. Am J Kidney Dis. 1994;23(4):537-542.
33. Fabrizi F, Dixit V, Messa P, Martin P. Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials. Vaccine. 2012;30(13):2295-2300.
34. Duranti E, Duranti D. Polymethylmethacrylate strengthens antibody response in hemodialysis patients not responding to hepatitis B vaccine: preliminary data. Minerva Med. 2011;102(6):469-474.
35. Tong NK, Beran J, Kee SA, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 2005;68(5):2298-2303.
36. Kong NC, Beran J, Kee SA, et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int. 2008;73(7):856-862.
37. Polito P, Di Lullo L, Iannacci GR, Cecilia A, Galderisi C, Gorini A. [Seroconversion and immune response after anti-HBV vaccination in patients on chronic hemodialysis: comparison of two vaccines]. G Ital Nefrol. 2011;28(5):525-530. [Article in Italian].
38. Surquin M, Tielemans CL, Kulcsár I, et al. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)adjuvanted hepatitis B vaccine. Kidney Int. 2010;77(3):247-255.
39. Surquin M, Tielemans C, Nortier J, et al. Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency. Hum Vaccin. 2011;7(9):913-918.
40. Tielemans CL, Vlasak J, Kosa D, et al. Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials. Vaccine. 2011;29(6): 1159-1166.
41. Janssen RS, Mangoo-Karim R, Pergola PE, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. Vaccine. 2013;31(46):5306-5313.
42. Janssen JM, Heyward WL, Martin JT, Janssen RS. Immunogenicity and safety of an investigational hepatitis B vaccine with a Tolllike receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus. Vaccine. 2015;33(7):833-837.
43. Tung J, Carlisle E, Smieja M, Kim PT, Lee CH. A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients. Am J Kidney Dis. 2010;56(4):713-719.
44. Jilg W, Schmidt M, Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis. 1989;160(5):766-769.
45. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet. 2000;355(9203):561-565.
46. Goffin E, Horsmans Y, Cornu C, Geubel A, Pirson Y. Acute hepatitis B infection after vaccination. Lancet. 1995;345(8944):263.
47. Fabrizi F, Di Filippo S, Marcelli D, et al. Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Long-term evaluation and cost-effectiveness analysis. Nephron. 1996;72(4): W536-543.